| Naslov: | Do double-expressor high-grade B-cell lymphomas really need intensified treatment : a report from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology Ljubljana |
|---|
| Avtorji: | ID Boltežar, Lučka (Avtor)
ID Rožman, Samo (Avtor)
ID Gašljević, Gorana (Avtor)
ID Grčar-Kuzmanov, Biljana (Avtor)
ID Jezeršek Novaković, Barbara (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2227-9059/12/2/275
 PDF - Predstavitvena datoteka, prenos (1004,13 KB)
MD5: 0B65236A0D9289CF428EF4900DDF9FCC
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients. |
|---|
| Ključne besede: | lymphoma, double-expressor lymphoma, oncology |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 25.12.2023 |
|---|
| Datum sprejetja članka: | 22.01.2024 |
|---|
| Datum objave: | 25.01.2024 |
|---|
| Založnik: | MDPI |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. 275-1-275-13 |
|---|
| Številčenje: | Vol. 12, no. 2 |
|---|
| Izvor: | Basel, Switzerland |
|---|
| PID: | 20.500.12556/DiRROS-18737  |
|---|
| UDK: | 616.4 |
|---|
| ISSN pri članku: | 2227-9059 |
|---|
| DOI: | 10.3390/biomedicines12020275 |
|---|
| COBISS.SI-ID: | 183791619 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 5. 2. 2024;
|
|---|
| Datum objave v DiRROS: | 18.04.2024 |
|---|
| Število ogledov: | 485 |
|---|
| Število prenosov: | 257 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
